Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Lymphoma Clinical Trials in Illinois | 664 Studies

Clinical Trials LymphomaIllinois

Lymphoma Clinical Trials in Illinois

Find 664 clinical trials for lymphoma near Illinois. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Illinois

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 501-520 of 664 trials

CompletedRituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's LymphomaRATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00460109·Scottsdale, Arizona and 164 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

Active not recruitingA Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including…NCT05458297·Anchorage, Alaska and 108 others

WithdrawnBrentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaThis phase II clinical trial studies how well giving brentuximab vedotin together with pembrolizumab in treating patients with peripheral T-cell lymphoma (PTCL) that has come back…NCT04795869·Chicago, Illinois

CompletedDexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell LymphomaRATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells.NCT00006345·Miami, Florida and 10 others

CompletedRituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's LymphomaRATIONALE: Monoclonal antibodies, such as rituximab and galiximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00117975·Washington D.C., District of Columbia and 67 others

CompletedCalaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic LeukemiaThis randomized clinical trial is studying giving calaspargase pegol together with combination chemotherapy to see how well it works compared with giving pegaspargase together…NCT00671034·Birmingham, Alabama and 26 others

RecruitingA Study of Carmustine With and Without Ethanol in Subjects With LymphomaA phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.NCT06915246·Goodyear, Arizona and 3 others

CompletedBendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular LymphomaRATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping…NCT01216683·Greenbrae, California and 226 others

CompletedCombination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin LymphomaThis phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma.NCT01026220·Birmingham, Alabama and 176 others

CompletedA Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded…NCT05144841·Orange, California and 70 others

TerminatedA Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyThe purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin plus rituximab in relapsed/refractory aggressive Non-Hodgkin lymphoma patients who are not…NCT01232556·Burbank, California and 176 others

CompletedSafety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's LymphomaThe purpose of the study is to assess the safety, tolerability, pharmacokinetics and immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or…NCT01471210·Los Angeles, California and 23 others

CompletedCT-011 MAb in DLBCL Patients Following ASCTAutologous peripheral blood stem cell transplantation combined with high dose chemotherapy is the treatment of choice given to patients with diffuse large-B cell lymphoma (DLBCL)…NCT00532259·La Jolla, California and 26 others

CompletedEpratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaRATIONALE: Monoclonal antibodies, such as epratuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00553501·San Diego, California and 42 others

Active not recruitingA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).NCT05578976·Tucson, Arizona and 330 others

Active not recruitingA Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with…NCT04404660·Duarte, California and 33 others

RecruitingPhase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic…NCT04150497·Los Angeles, California and 18 others

UnknownCombination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin LymphomaThe purpose of this study is to evaluate the effects, good and bad of a new drug called ixazomib (also called MLN9708), when it is given along with a common treatment combination…NCT02481310·Chicago, Illinois and 4 others

Active not recruitingA Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)This study has 2 parts.NCT05020015·Birmingham, Alabama and 14 others

RecruitingSYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryInternational registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool…NCT03452774·Birmingham, Alabama and 67 others

PreviousPage 26 of 34Next

Other Conditions in Illinois

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia